MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Zimmer Biomet completes ZimVie spinoff

Zimmer Biomet completes ZimVie spinoff

By

ZimVieZimmer Biomet (NYSE:ZBH) announced today that it completed the spinoff of ZimVie, its former dental and spine businesses.

Shares of ZimVie started trading on the Nasdaq market today under the “ZIMV” ticker. ZIMV shares were down more than 26% to $28 apiece by the afternoon. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly.

Warsaw, Indiana-based Zimmer Biomet previously announced the spinoff of its spine and dental businesses in February 2021. In that same month, ZB said Vafa Jamali would serve as the CEO of the spinoff.

The new 2,700-employee company has its headquarters in Westminster, Colorado. It’s expecting revenues to stay flat at about $1 billion this year as it pays down debt and fixes operational issues in the spine business, Jamali told MassDevice and Medical Design & Outsourcing shortly after ringing in the Nasdaq today.

“We’re going to have a year of resetting and sorting out all these pieces. And then you’ll see us accelerate on some of the more innovation-focused areas and goals,” Jamali said. (Go to MDO to read much more from Jamali — including where he sees ZimVie innovating.)

Last month, when announcing its fourth-quarter earnings, Zimmer Biomet confirmed the planned completion date for the ZimVie spinoff was March 1, 2022.

“The spinoff of ZimVie marks a major milestone in the active portfolio management of Zimmer Biomet as we continue to strengthen our position as a global leader in the medtech space,” ZB CEO Bryan Hanson said in a news release.  “We are confident that this transaction will create shareholder value for both companies and will allow us to increase our focus and enhance revenue growth for our core businesses.”

Zimmer Biomet achieved the spinoff by distributing 80.3% of the shares of ZimVie to holders of Zimmer Biomet common stock today, March 1, 2022, with Zimmer Biomet stockholders receiving one share of ZimVie common stock for every ten shares of Zimmer Biomet common stock held at the close of business on the record date of Feb. 15, 2022.

Fractional shares of ZimVie common stock will not be distributed to Zimmer Biomet shareholders and will instead be aggregated and sold in the open market. Net proceeds from the sale of fractional shares will be distributed pro rata in cash payments to the Zimmer Biomet shareholders who otherwise would have received fractional shares of ZimVie common stock.

Zimmer Biomet previously announced that the deal includes ZB receiving a $501 million cash payment from ZimVie, which means that the new company will have roughly $500 million in debt.

In case you missed it

RSS From Medical Design & Outsourcing

  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heat wave in Texas took at least six power plants offline Friday with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]
  • Here’s where Harvard’s engineering dean sees medtech research going
    Surgical robotics, artificial intelligence, and combatting climate change are but some of the priorities that have Harvard’s engineering school dean excited. Speaking today at DeviceTalks Boston, Frank J. Doyle III described the Harvard John A. Paulson School of Engineering and Applied Sciences as a “well-kept secret” historically. But Harvard engineering is staking out a strong position when it… […]
  • gBETA Medtech accelerator picks its next startups
    The gBETA Medtech virtual accelerator today named the five startups that will participate in the spring program leading up to the June 21 showcase day. The five startups for the spring 2022 cohort are: Mother of Fact: This mobile app for moms with babies offers nutrition tracking, preventative monitoring and daily coaching from licensed dietitians… […]